Efficacy & Safety of Dalpiciclib With Endocrine Therapy as Adjuvant

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04538833` - GM1 in the Treatment of Neurotoxicity Induced by Albumin-bound Paclitaxel	Phase 2
Completed	`NCT04436744` - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)	Phase 2
Completed	`NCT02187744` - A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)	Phase 3
Terminated	`NCT01155063` - Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients	N/A
Recruiting	`NCT03949634` - Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)	Phase 3
Active, not recruiting	`NCT05730647` - Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
Terminated	`NCT01919229` - A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)	Phase 2
Active, not recruiting	`NCT04293393` - Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients	Phase 2
Completed	`NCT00713141` - Evaluation of Brain Function Before and After Standard Chemotherapy for Early Breast Cancer	N/A
Not yet recruiting	`NCT06404736` - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer	Phase 2
Not yet recruiting	`NCT06404463` - QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer	Phase 2
Not yet recruiting	`NCT06435104` - Aromatherapy in the Treatment of Early Breast Cancer	Phase 2
Recruiting	`NCT03520894` - Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer	N/A
Completed	`NCT03786198` - Activity Program During Aromatase Inhibitor Therapy	N/A
Completed	`NCT01613352` - Feasibility of Ambulatory Surgery for Early Breast Cancer	N/A
Completed	`NCT02738970` - A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)	Phase 1
Recruiting	`NCT01792726` - A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.	N/A
Completed	`NCT00323479` - Arthralgia During Anastrozole Therapy for Breast Cancer	Phase 4
Completed	`NCT03493854` - A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer	Phase 3
Recruiting	`NCT04291378` - The DBCG Proton Trial: Photon Versus Proton Radiation Therapy for Early Breast Cancer	N/A

NCT number	NCT06341894
Study type	Interventional
Source	The First Affiliated Hospital with Nanjing Medical University
Contact	Xiaoan Liu, Professor
Phone	025-68308162
Email	liuxiaoan@126.com
Status	Recruiting
Phase	Phase 2
Start date	November 17, 2023
Completion date	June 2029

Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms